A detailed history of Sjs Investment Consulting Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Sjs Investment Consulting Inc. holds 54 shares of EXEL stock, worth $1,964. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54
Previous 54 -0.0%
Holding current value
$1,964
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 16, 2024

SELL
$19.25 - $24.13 $38 - $48
-2 Reduced 3.57%
54 $1,000
Q3 2023

Oct 17, 2023

BUY
$19.04 - $22.74 $38 - $45
2 Added 3.7%
56 $1,000
Q2 2023

Jul 13, 2023

SELL
$18.17 - $20.48 $18 - $20
-1 Reduced 1.82%
54 $1,000
Q1 2023

Apr 20, 2023

BUY
$16.3 - $19.41 $81 - $97
5 Added 10.0%
55 $1,000
Q4 2022

Jan 23, 2023

BUY
$14.96 - $17.39 $239 - $278
16 Added 47.06%
50 $0
Q3 2022

Oct 13, 2022

BUY
$15.68 - $22.27 $407 - $579
26 Added 325.0%
34 $1,000
Q1 2022

May 05, 2022

BUY
$17.03 - $22.67 $136 - $181
8 New
8 $0

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Sjs Investment Consulting Inc. Portfolio

Follow Sjs Investment Consulting Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sjs Investment Consulting Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sjs Investment Consulting Inc. with notifications on news.